DHX32: A Potential Drug Target and Biomarker for Pre-mRNA Splicing

Target Name: DHX32

NCBI ID: G55760

DHX32

DHX32: A Potential Drug Target and Biomarker for Pre-mRNA Splicing

The pre-mRNA splicing process is a critical step in the regulation of gene expression in eukaryotic cells. It involves the removal of non-coding introns from the pre-mRNA and the addition of exons from aDNA template to create a functional RNA molecule that can be translated into protein. The protein responsible for this process is DHX32, which is a member of the X-linked RNA helicase family. In this article, we will explore DHX32 as a potential drug target and biomarker for pre-mRNA splicing disorders.

DHX32: Structure and Function

DHX32 is a 21 kDa protein that is expressed in most tissues of the body. It is a member of the X-linked RNA helicase family, which includes several proteins that are involved in the regulation of gene expression in females. DHX32 is localized to the nucleus and is predominantly composed of a single polypeptide chain.

DHX32 functions as a pre-mRNA splicing factor by promoting the loading of the pre-mRNA onto the splicing machinery. It does this by interacting with the protein CoRAS2, which is also a pre-mRNA splicing factor. CoRAS2 is a GTPase that is involved in the regulation of gene expression, and it functions as a negative regulator of DHX32.

DHX32 is also known for its role in the regulation of microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by binding to specific target genes and regulating their translation into protein. DHX32 has been shown to interact with miRNA-21, a miRNA that is involved in the regulation of cell proliferation and survival.

DHX32 is also involved in the regulation of gene expression in the context of RNA polymerase II (RNA-II). RNA-II is a complex protein that is responsible for the transcription of DNA into RNA. DHX32 has been shown to interact with the protein p16, which is a component of RNA-II.

DHX32 is a potent inhibitor of RNA polymerase II-mediated gene expression. It has been shown to inhibit the activity of RNA-II in the presence of an agonist and to increase the rate of degradation of RNA-II in cells treated with an agonist.

DHX32 is also a potential biomarker for pre-mRNA splicing disorders. Pre-mRNA splicing disorders are a group of genetic disorders that are characterized by the abnormal regulation of pre-mRNA splicing. These disorders can be caused by mutations in genes involved in the pre-mRNA splicing process, including DHX32.

DHX32 has been shown to be a missense mutant in a patient with pre-mRNA splicing disorder. The patient had a defect in the regulation of pre-mRNA splicing and was affected by a range of symptoms, including developmental delays, hearing loss, and learning difficulties. The analysis of the patient's DNA revealed a mutation in the DHX32 gene.

Conclusion

In conclusion, DHX32 is a protein that is involved in the regulation of pre-mRNA splicing in eukaryotic cells. It functions as a pre-mRNA splicing factor and is also involved in the regulation of miRNA and RNA polymerase II-mediated gene expression. DHX32 is a potential drug target and biomarker for pre-mRNA splicing disorders. Further research is needed to fully understand the role of DHX32 in

Protein Name: DEAH-box Helicase 32 (putative)

The "DHX32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets